Basic Information
Pregabalin Zentiva
Regulatory Information
EMEA/H/C/003900
July 17, 2015
May 21, 2015
18
October 17, 2024
Company Information
Czech Republic
U kabelovny 130 201 37 Prague 10
Zentiva, k.s.
Drug Classification
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication **Neuropathic pain** - Pregabalin Zentiva is indicated for the treatment of peripheral and central neuropathic pain in adults. **Epilepsy** - Pregabalin Zentiva is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation. **Generalised anxiety disorder** - Pregabalin Zentiva is indicated for the treatment of generalised anxiety disorder (GAD) in adults.
Overview Summary
This is a summary of the European public assessment report (EPAR) for Pregabalin Zentiva. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Pregabalin Zentiva. For practical information about using Pregabalin Zentiva, patients should read the package leaflet or contact their doctor or pharmacist.